These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 20924644)

  • 1. Combining functional imaging and interstitial pressure measurements to evaluate two anti-angiogenic treatments.
    Leguerney I; Lassau N; Koscielny S; Rodrigues M; Massard C; Rouffiac V; Benatsou B; Thalmensi J; Bawa O; Opolon P; Peronneau P; Roche A
    Invest New Drugs; 2012 Feb; 30(1):144-56. PubMed ID: 20924644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting angiogenesis in bladder cancer.
    Elfiky AA; Rosenberg JE
    Curr Oncol Rep; 2009 May; 11(3):244-9. PubMed ID: 19336017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sorafenib enhances the in vitro anti-endothelial effects of low dose (metronomic) chemotherapy.
    Murray A; Little SJ; Stanley P; Maraveyas A; Cawkwell L
    Oncol Rep; 2010 Oct; 24(4):1049-58. PubMed ID: 20811688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RAIN-Droplet: a novel 3D in vitro angiogenesis model.
    Zeitlin BD; Dong Z; Nör JE
    Lab Invest; 2012 Jul; 92(7):988-98. PubMed ID: 22565576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Challenges and pitfalls of combining targeted agents in phase I studies.
    Cannistra SA
    J Clin Oncol; 2008 Aug; 26(22):3665-7. PubMed ID: 18669449
    [No Abstract]   [Full Text] [Related]  

  • 6. Paclitaxel in combination with sorafenib and bevacizumab in patients with locally advanced or metastatic solid tumors.
    Schultheis B; Neumann H; Roy R; Heuer V; Kummer G; Strumberg D
    Int J Clin Pharmacol Ther; 2012 Jan; 50(1):72-3. PubMed ID: 22192652
    [No Abstract]   [Full Text] [Related]  

  • 7. Sorafenib and bevacizumab for recurrent metastatic hepatoblastoma: stable radiographic disease with decreased AFP.
    Marsh AM; Lo L; Cohen RA; Feusner JH
    Pediatr Blood Cancer; 2012 Nov; 59(5):939-40. PubMed ID: 22492703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Noninvasive contrast-enhanced US quantitative assessment of tumor microcirculation in a murine model: effect of discontinuing anti-VEGF therapy.
    Guibal A; Taillade L; Mulé S; Comperat E; Badachi Y; Golmard JL; Le Guillou-Buffello D; Rixe O; Bridal SL; Lucidarme O
    Radiology; 2010 Feb; 254(2):420-9. PubMed ID: 20093514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular toxicities: clues to optimal administration of vascular endothelial growth factor signaling pathway inhibitors.
    Snider KL; Maitland ML
    Target Oncol; 2009 Apr; 4(2):67-76. PubMed ID: 19373440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of sorafenib on intra-tumoral interstitial fluid pressure and circulating biomarkers in patients with refractory sarcomas (NCI protocol 6948).
    Raut CP; Boucher Y; Duda DG; Morgan JA; Quek R; Ancukiewicz M; Lahdenranta J; Eder JP; Demetri GD; Jain RK
    PLoS One; 2012; 7(2):e26331. PubMed ID: 22347360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contrast ultrasonography: necessity of linear data processing for the quantification of tumor vascularization.
    Peronneau P; Lassau N; Leguerney I; Roche A; Cosgrove D
    Ultraschall Med; 2010 Aug; 31(4):370-8. PubMed ID: 20577941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Perfusion MDCT enables early detection of therapeutic response to antiangiogenic therapy.
    Sabir A; Schor-Bardach R; Wilcox CJ; Rahmanuddin S; Atkins MB; Kruskal JB; Signoretti S; Raptopoulos VD; Goldberg SN
    AJR Am J Roentgenol; 2008 Jul; 191(1):133-9. PubMed ID: 18562736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation.
    Thompson Coon J; Hoyle M; Green C; Liu Z; Welch K; Moxham T; Stein K
    Health Technol Assess; 2010 Jan; 14(2):1-184, iii-iv. PubMed ID: 20028613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dynamic contrast-enhanced computed tomography imaging biomarkers correlated with immunohistochemistry for monitoring the effects of sorafenib on experimental prostate carcinomas.
    Cyran CC; von Einem JC; Paprottka PM; Schwarz B; Ingrisch M; Dietrich O; Hinkel R; Bruns CJ; Clevert DA; Eschbach R; Reiser MF; Wintersperger BJ; Nikolaou K
    Invest Radiol; 2012 Jan; 47(1):49-57. PubMed ID: 21934514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Everolimus augments the effects of sorafenib in a syngeneic orthotopic model of hepatocellular carcinoma.
    Piguet AC; Saar B; Hlushchuk R; St-Pierre MV; McSheehy PM; Radojevic V; Afthinos M; Terracciano L; Djonov V; Dufour JF
    Mol Cancer Ther; 2011 Jun; 10(6):1007-17. PubMed ID: 21487053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination therapy: intermittent sorafenib with bevacizumab yields activity and decreased toxicity.
    Lee JM; Sarosy GA; Annunziata CM; Azad N; Minasian L; Kotz H; Squires J; Houston N; Kohn EC
    Br J Cancer; 2010 Feb; 102(3):495-9. PubMed ID: 20051952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma.
    Escudier B; Lassau N; Angevin E; Soria JC; Chami L; Lamuraglia M; Zafarana E; Landreau V; Schwartz B; Brendel E; Armand JP; Robert C
    Clin Cancer Res; 2007 Mar; 13(6):1801-9. PubMed ID: 17363536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of choroidal neovascularisation in mice by systemic administration of the multikinase inhibitor, sorafenib.
    Chung EJ; Yoo S; Lim HJ; Byeon SH; Lee JH; Koh HJ
    Br J Ophthalmol; 2009 Jul; 93(7):958-63. PubMed ID: 19028740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes.
    Alfaro C; Suarez N; Gonzalez A; Solano S; Erro L; Dubrot J; Palazon A; Hervas-Stubbs S; Gurpide A; Lopez-Picazo JM; Grande-Pulido E; Melero I; Perez-Gracia JL
    Br J Cancer; 2009 Apr; 100(7):1111-9. PubMed ID: 19277038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of antiangiogenesis therapy: bevacizumab and beyond.
    Cortés-Funes H
    Clin Transl Oncol; 2009 Jun; 11(6):349-55. PubMed ID: 19531449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.